NEW YORK, Dec. 4, 2014 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), concerning the proposed acquisition of Avanir by Otsuka Pharmaceutical Co., Ltd.  Avanir shareholders seeking more information about this acquisition are advised to contact Carl Stine at (212) 759-4600 or cstine@wolfpopper.com.

The investigation concerns whether the Avanir directors are breaching their fiduciary duties by failing to adequately maximize shareholder value.  Under the terms of the merger agreement, Avanir shareholders will receive $17.00 in cash for each share of Avanir they own.  The proposed transaction has an equity value of $2.9 billion.  However, the offer price is below the median Street price target of $17.71 per share.

Wolf Popper LLP has extensive experience representing investors in mergers and acquisition lawsuits and has successfully ensured that investors receive the maximum compensation.  Twelve Wolf Popper attorneys were named Rising Stars or Super Lawyers in the 2014 Super Lawyers New York City Metro Edition, including Wolf Popper partner Carl Stine, who was included in the Super Lawyers Top 100 List for the New York City Metro area.  View Wolf Popper attorney biographies at www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLP
845 Third Avenue
New York, New York 10022
Telephone: 212-759-4600
Toll Free Tel: 877-370-7703
Toll Free Fax: 877-370-7704
Email: cstine@wolfpopper.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wolf-popper-llp-investigates-claims-that-the-proposed-acquisition-of-avanir-pharmaceuticals-inc-may-not-be-in-the-best-interests-of-its-investors-300005006.html

SOURCE Wolf Popper LLP